Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 5, Mai 2008
Page(s) 511 - 520
Section M/S revues
DOI https://doi.org/10.1051/medsci/2008245511
Publié en ligne 15 mai 2008
  1. Smeds AI, Eklund PC, Sjöholm RE, et al. Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts. J Agric Food Chem 2007; 55 : 1337–46. [Google Scholar]
  2. Hall C III, Tulbek M, Xu, Y. Flaxseed. Adv Food Nutr Res 2006; 51 : 1–97. [Google Scholar]
  3. Lainé E, Hano C, Lamblin F. Les lignanes phyto-œstrogènes du lin sont ils des bienfaiteurs méconnus ? Phytothérapie 2007; 5 : 121–8. [Google Scholar]
  4. Cho JY, Kim AR, Yoo ES, et al. Immunomodulatory effect of arctigenin, a lignan compound, on tumour necrosis factor-a and nitric oxide production and lymphocyte proliferation. J Pharm Pharmacol 1999; 51 : 1267–73. [Google Scholar]
  5. Adlercreutz H. Phyto-œstrogens and cancer. Lancet Oncology 2002; 6 : 364–73. [Google Scholar]
  6. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993; 44 : 147–53. [Google Scholar]
  7. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005; 94 : 461–7. [Google Scholar]
  8. Martin ME, Haourigui M, Pelissero C, et al. Interactions between phytœstrogens and human sex steroid binding protein. Life Sci 1996; 58 : 429–36. [Google Scholar]
  9. Schottner M, Spiteller G. Lignans interfering with 5alpha-dihydrotestosterone binding to human sex hormone-binding globulin. J Nat Prod 1998; 61 : 119–21. [Google Scholar]
  10. Li D, Yee JA, Thompson LU, Yan L. Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 1999; 142 : 91–6. [Google Scholar]
  11. Bylund A, Saarinen N, Zhang JX, et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med (Maywood) 2005; 230 : 217–23. [Google Scholar]
  12. Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 2005; 11 : 3828–35. [Google Scholar]
  13. Danbara N, Yuri T, Tsujita-Kyutoku M, et al. Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 2005; 25 : 2269–76. [Google Scholar]
  14. Magee PJ, McGlynn H, Rowland. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 2004; 208 : 35–41. [Google Scholar]
  15. Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion, and migration in vitro. Br Can Res Treat 2003; 80 : 163–70. [Google Scholar]
  16. Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007; 13 : 1061–7. [Google Scholar]
  17. Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flax-seed. Mol Cell Biochem 1997; 168 : 117–23. [Google Scholar]
  18. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999; 202 : 91–100. [Google Scholar]
  19. Imbert F. Discovery of podophyllotoxin. Biochimie 1998; 80 : 207–22. [Google Scholar]
  20. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000; 54 : 115–20. [Google Scholar]
  21. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer ? Lung Cancer 2007; 57 : 30–4. [Google Scholar]
  22. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer : have we made any progress over the last 25 years ? The Oncologist 2007; 12 : 1096–104. [Google Scholar]
  23. Sung PA, Libura J, Richardson C. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations : new insights and new questions. DNA Repair 2006; 5 : 1109–18. [Google Scholar]
  24. Guenfoudi-Roullaud MP, Menat C, Girard F, et al. Etoposide et risque leucémogène. J Pharm Clin 1998; 17 : 71–3. [Google Scholar]
  25. Schacter L. Etoposide phosphate : what, why, where, and how ? Semin Oncol 1996; 23 : 1–7. [Google Scholar]
  26. Hande K. Topoisomerase II inhibitors. Update Cancer Ther 2006; 1 : 3–15. [Google Scholar]
  27. Champoux JJ. DNA topoisomerases : structure, function, and mechanism. Annu Rev Biochem 2001; 70 : 369–413. [Google Scholar]
  28. Wang JC. Cellular roles of DNA topoisomerases : a molecular perspective. Nat Rev Mol Cell Biol 2002; 3 : 430–40. [Google Scholar]
  29. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 2007; 104 : 11014–9. [Google Scholar]
  30. Leroy D, Kajava AV, Frei C, Gasser SM. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 2001; 40 : 1624–34. [Google Scholar]
  31. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252 : 9–18. [Google Scholar]
  32. Cosse JP, Sermeus A, Vannuvel K, et al. Differential effects of hypoxia on etoposide induced apoptosis according to the cancer lines. Mol Cancer 2007; 6 : 61. [Google Scholar]
  33. Clifford B, Beljin M, Stark GR, Taylor WR. G2 arrest in response to topoisomerase II inhibitors the Role of p53. Cancer Res 2003; 63 : 4074–81. [Google Scholar]
  34. Bjørling-Poulsen M, Issinger OG. CDNA array analysis of alterations in gene expression in the promyelocytic leukemia cell line, HL-60, after apoptosis induction with etoposide. Apoptosis 2003; 8 : 377–88. [Google Scholar]
  35. Okada Y, Tosaka A, Nimura Y, et al. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001; 272 : 141–8. [Google Scholar]
  36. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775 : 237–62. [Google Scholar]
  37. Castro MA, Miguel del Corral JM, Gordaliza M, et al. Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin J Med Chem 2004; 47 : 1214–22. [Google Scholar]
  38. Magedov IV, Manpadi M, Van Slambrouck S, et al. Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. J Med Chem 2007; 50 : 5183–92. [Google Scholar]
  39. Wiltermann AM, Bender RP, Godfrey M, et al. Topoisomerase II-drug inteaction domains : identification of substituents on etoposide that interact with the enzyme. Biochemistry 2007; 46 : 8217–25. [Google Scholar]
  40. Zhang FM, Yao XJ, Tu YQ. Synthesis and biological evaluation of new 4β-5-Fu-substituted 4’-demethylepipodophyllotoxin derivatives. Molecules 2006; 11 : 849–57. [Google Scholar]
  41. Medarde M, Ramos AC, Caballero E, et al. A New approach to the synthesis of podophyllotoxin based on epimerization reactions. Tetrahedron Lett 1996; 37 : 2663–66. [Google Scholar]
  42. Farkya S, Bisaria VS, Srivastava AK. Biotechnological aspects of the production of the anticancer drug podophyllotoxin. Appl Microbiol Biotechnol 2004; 65 : 504–19 [Google Scholar]
  43. Gordaliza M, García PA, Miguel del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin : distribution, sources, applications and new cytotoxic derivatives Toxicon 2004; 44 : 441–59 [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.